Literature DB >> 19156859

HIF prolyl hydroxylase inhibition augments dopamine release in the rat brain in vivo.

Louise Witten1, Thomas Sager, Kenneth Thirstrup, Jens Leander Johansen, Dorrit Bjerg Larsen, Liliana P Montezinho, Arne Mørk.   

Abstract

The transcription factor hypoxia-inducible factor (HIF) is essential for the activation of several genes that promote the survival of cells exposed to oxidative stress. Expression of tyrosine hydroxylase (TH), which is the rate-limiting enzyme in the dopamine (DA) synthesis, is one of the genes that are positively regulated by HIF. Accordingly, HIF induction results in elevated DA release in various cell lines in vitro. HIF prolyl hydroxylase (HPH) is critically involved in the negative regulation of HIF levels. We investigated the in vivo effects of the HPH inhibitor FG0041 on brain DA function in rats by microdialysis in freely moving rats, locomotor activity, and Western blot analysis. Administration of FG0041 (10 mg/kg i.p.), as an acute (single injection), or as subchronic (once daily for 6 days) treatment and cobalt chloride (CoCl2) (60 mg/kg s.c.) potentiated potassium (K+) induced increases in extracellular levels of DA levels in the rat striatum. The increase in extracellular DA of freely moving rats was sought in relationship to locomotor activity in rats. A significant increase in locomotor activity was observed in FG0041-treated rats compared with vehicle on a cocaine challenge. In support of these findings, protein levels of TH in the rat brain stem were increased after treatment with FG0041. These data indicate that FG0041 augments DA function in the rat brain. Inhibition of HPH enhances DA function by increasing DA release, which has implications for the use of HIF induction in the treatment of neurodegenerative diseases. Copyright 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19156859     DOI: 10.1002/jnr.21988

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  6 in total

Review 1.  Hypoxia inducible factor-1 as a target for neurodegenerative diseases.

Authors:  Z Zhang; J Yan; Y Chang; S ShiDu Yan; H Shi
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

2.  Multiple N-of-1 trials to investigate hypoxia therapy in Parkinson's disease: study rationale and protocol.

Authors:  Jules M Janssen Daalen; Marjan J Meinders; Federica Giardina; Kit C B Roes; Bas C Stunnenberg; Soania Mathur; Philip N Ainslie; Dick H J Thijssen; Bastiaan R Bloem
Journal:  BMC Neurol       Date:  2022-07-14       Impact factor: 2.903

3.  Complement C1q is hydroxylated by collagen prolyl 4 hydroxylase and is sensitive to off-target inhibition by prolyl hydroxylase domain inhibitors that stabilize hypoxia-inducible factor.

Authors:  Serafim Kiriakidis; Simon S Hoer; Natalie Burrows; Gloria Biddlecome; Moddasar N Khan; Cyrille C Thinnes; Christopher J Schofield; Norma Rogers; Marina Botto; Ewa Paleolog; Patrick H Maxwell
Journal:  Kidney Int       Date:  2017-05-12       Impact factor: 10.612

4.  D1 receptor-mediated endogenous tPA upregulation contributes to blood-brain barrier injury after acute ischaemic stroke.

Authors:  Yan Wang; Xiaona Wang; Xinyu Zhang; Shuang Chen; Yanyun Sun; Wenlan Liu; Xinchun Jin; Guoqing Zheng
Journal:  J Cell Mol Med       Date:  2020-07-06       Impact factor: 5.310

Review 5.  HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons.

Authors:  Andrey A Poloznikov; Stepan A Nersisyan; Dmitry M Hushpulian; Eliot H Kazakov; Alexander G Tonevitsky; Sergey V Kazakov; Valery I Vechorko; Sergey V Nikulin; Julia A Makarova; Irina G Gazaryan
Journal:  Front Pharmacol       Date:  2021-01-29       Impact factor: 5.810

6.  Competitive HIF Prolyl Hydroxylase Inhibitors Show Protection against Oxidative Stress by a Mechanism Partially Dependent on Glycolysis.

Authors:  Ann-Louise Bergström; Karina Fog; Thomas Nikolaj Sager; Anne Techau Bruun; Kenneth Thirstrup
Journal:  ISRN Neurosci       Date:  2013-12-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.